Results 151 to 160 of about 6,944 (246)

SAFETY OF GLP-1RA THERAPY: SIDE EFFECTS AND THE NEED FOR MONITORING [PDF]

Małgorzata Piasta, Miłosz Mandryk, Magdalena Grzesiak, Oskar Szymański   +3 more
openalex   +1 more source

GLP-1RA use improves outcomes post partial nephrectomy in T2DM patients with RCC: A TriNetX study. [PDF]

BJUI Compass
Kwon S, Wardrop F, Gonzalez D, Ryan F, Khutsishvili L, Turner R, Deameh MG, Whalen MJ.   +7 more
europepmc   +1 more source

Kidney Effectiveness and Safety of Adding Spironolactone in Patients With Type 2 Diabetes Receiving Renin–Angiotensin System Inhibitors Therapy

Clinical and Translational Science, Volume 19, Issue 3, March 2026.
ABSTRACT We evaluated the renal outcomes and safety of spironolactone added to renin–angiotensin system inhibitors (RASis) among patients with type 2 diabetes (T2D), given its uncertain role alongside RASis, the cornerstone of T2D with renal disease management.
Wei‐Ren Lin, Tzu‐Shan Huang, Ho‐Hsiang Chang, Jo‐Yen Chao, Yi‐Hsin Chang, Chen‐Yi Yang, Huang‐Tz Ou, Wei‐Hung Lin   +7 more
wiley   +1 more source

GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway

, 2023
Jie Xiang, Liyan Qin, Jinling Zhong, Xia Ning, Yuzhen Liang   +4 more
openalex   +2 more sources

GLP-1RA precision medicine in people with type 2 diabetes: current insights and future prospects. [PDF]

J Clin Invest
Cardoso P, Dennis JM, Pearson ER.
europepmc   +1 more source

Use of sodium‐glucose cotransporter‐2 inhibitors among older adults with type 2 diabetes mellitus in British Columbia

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 1915-1923, March 2026.
Abstract Aims Clinical guidelines recommend sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) for individuals with type 2 diabetes mellitus (T2DM) and established or high risk of cardiorenal disease. This study examined real‐world SGLT2i use patterns among older adults with T2DM in British Columbia, Canada.
Hanin Harbi, Gregory Carney, Colin Dormuth, Jacob Volmer Stidsen, Iliana Lega, Lisa M. McCarthy, Guillaume Grenet, Anshula Ambasta, Raha Eskandari, Anton Pottegård, Wade Thompson   +10 more
wiley   +1 more source

Association between glucagon‐like peptide‐1 receptor agonists and risk of dementia in older adults with type 2 diabetes: A target trial emulation

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 1984-1996, March 2026.
Abstract Aim Type 2 diabetes (T2D) is associated with increased dementia risk, but comparative data across newer glucose‐lowering therapies remain limited. We examined whether the initiation of GLP‐1 receptor agonists (GLP‐1 RAs) was associated with incident dementia compared with DPP4 inhibitors (DPP4is) and SGLT2 inhibitors (SGLT2is) in older adults ...
Ting Zhou, Huilin Tang, Bingyu Zhang, Dazheng Zhang, Yiwen Lu, Lu Li, Jiajie Chen, Yong Chen, David A. Asch, Yong Chen   +9 more
wiley   +1 more source

Deintensification of basal-bolus insulin after initiation of GLP-1RA in patients with type 2 diabetes under routine care

, 2021
Benedetta Maria Bonora, Mauro Rigato, Vera Frison, M. Dambrosio, Federica Tadiotto, Annunziata Lapolla, Natalino Simioni, Agostino Paccagnella, Angelo Avogaro, Gian Paolo Fadini   +9 more
openalex   +2 more sources

Beyond diabetes and obesity: GLP‐1 receptor agonists in disrupting the vicious cycle of metabolic dysfunction and neuroinflammation

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 1622-1637, March 2026.
Abstract Neurodegenerative diseases, including debilitating conditions like Alzheimer's and Parkinson's, are characterized by progressive neuronal loss, a process fundamentally driven by persistent chronic neuroinflammation and central metabolic dysfunction.
Renata Spezani, Carlos A. Mandarim‐de‐Lacerda   +1 more
wiley   +1 more source

GLP-1RA: New Hope in Obesity Therapy

Journal of Biosciences and Medicines
Danfeng Zhang, Hongyun Lu
openaire   +1 more source